Neuraxis, INC (NRXS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Neuraxis, INC's filing signal turned positive.

Neuraxis, Inc. is a growth-stage medical technology company specializing in neuromodulation therapies for chronic gastrointestinal (GI) digestive system disorders, particularly disorders of the gut-brain interaction (DGBIs). The company's proprietary IB-Stim therapy, based on Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, is FDA-cleared for functional abdominal pain associated with IBS and functional dyspepsia in patients aged 8 and older. Neuraxis also offers the RED (Rectal Expulsion Device) for evaluating rectal function in adults. The company focuses on unmet needs in pediatrics and adults, aiming to provide drug-free alternatives that improve patient outcomes. Its strategy involves expanding clinical trials for additional indications and securing broader insurance coverage.

Revenue is primarily driven by the sale of its IB-Stim device to healthcare providers, with sales generally not being seasonal. The company's revenue is also influenced by the average selling price of IB-Stim, production volume, and customer mix.